| abstract |
The invention relates to a dose of 2.5 mg of the pentasaccharide methyl O-(2,3,4-tri-O-methyl-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-β-D-glucopyranosyl uronic acid)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2,3-di-O-methyl-α-L-idopyranosyl uronic acid)-(1→)-2,3,6-tri-O-sulfo-α-D-glucopyranoside or a pharmaceutically acceptable salt thereof for use in therapy, in particular for the treatment and/or secondary prophylaxis of venous thromboembolic events in patients with deep venous thrombosis. |